Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Receivables (2016 - 2022)

Edesa Biotech's Receivables history spans 10 years, with the latest figure at $2.5 million for Q2 2022.

  • For Q2 2022, Receivables fell 69.38% year-over-year to $2.5 million; the TTM value through Jun 2022 reached $2.5 million, down 69.38%, while the annual FY2021 figure was $6.3 million, 7141.99% up from the prior year.
  • Receivables for Q2 2022 was $2.5 million at Edesa Biotech, up from $2.3 million in the prior quarter.
  • Across five years, Receivables topped out at $8.2 million in Q2 2021 and bottomed at $7339.0 in Q4 2018.
  • The 5-year median for Receivables is $109600.0 (2019), against an average of $2.0 million.
  • The largest annual shift saw Receivables plummeted 83.63% in 2020 before it skyrocketed 14379.72% in 2021.
  • A 5-year view of Receivables shows it stood at $7339.0 in 2018, then soared by 1393.39% to $109600.0 in 2019, then surged by 53.31% to $168030.0 in 2020, then surged by 3176.4% to $5.5 million in 2021, then plummeted by 54.52% to $2.5 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Receivables are $2.5 million (Q2 2022), $2.3 million (Q1 2022), and $5.5 million (Q4 2021).